LGALS3 and liver disorder: Inhibition of galectin-3 in liver disease is hypothesized to offer therapeutic potential (Mackinnon et al., 2023), with early clinical studies starting to demonstrate effects on biomarkers of liver injury (Lindmark et al., 2023).